Analysis of DNA methylation in cancer: location revisited - PubMed (original) (raw)

Review

. 2018 Jul;15(7):459-466.

doi: 10.1038/s41571-018-0004-4.

Sophie C Joosten 2, Zheng Feng 1, Tim C de Ruijter 2, Muriel X Draht 1, Veerle Melotte 1, Kim M Smits 1 2, Jurgen Veeck 2, James G Herman 3, Leander Van Neste 1, Wim Van Criekinge 4, Tim De Meyer 5, Manon van Engeland 6

Affiliations

• PMID: 29666440
• DOI: 10.1038/s41571-018-0004-4

Review

Analysis of DNA methylation in cancer: location revisited

Alexander Koch et al. Nat Rev Clin Oncol. 2018 Jul.

Erratum in

• Author Correction: Analysis of DNA methylation in cancer: location revisited.
  Koch A, Joosten SC, Feng Z, de Ruijter TC, Draht MX, Melotte V, Smits KM, Veeck J, Herman JG, Van Neste L, Van Criekinge W, de Meyer T, van Engeland M. Koch A, et al. Nat Rev Clin Oncol. 2018 Jul;15(7):467. doi: 10.1038/s41571-018-0028-9. Nat Rev Clin Oncol. 2018. PMID: 29713045

Abstract

Changes in DNA methylation in cancer have been heralded as promising targets for the development of powerful diagnostic, prognostic, and predictive biomarkers. Despite the existence of more than 14,000 scientific publications describing DNA methylation-based biomarkers and their clinical associations in cancer, only 14 of these biomarkers have been translated into a commercially available clinical test. Methodological and experimental obstacles are both major causes of this disparity, but the genomic location of a DNA methylation-based biomarker is an intrinsic and essential property that also has an important and often overlooked role. Here, we examine the importance of the location of DNA methylation for the development of cancer biomarkers, and take a detailed look at the genomic location and other relevant characteristics of the various biomarkers with commercially available tests. We also emphasize the value of publicly available databases for the development of DNA methylation-based biomarkers and the importance of accurate reporting of the full methodological details of research findings.

PubMed Disclaimer

Similar articles

• The Role of DNA Methylation in Cancer.
  Lakshminarasimhan R, Liang G. Lakshminarasimhan R, et al. Adv Exp Med Biol. 2016;945:151-172. doi: 10.1007/978-3-319-43624-1_7. Adv Exp Med Biol. 2016. PMID: 27826838 Free PMC article. Review.
• DNA methylation based biomarkers in colorectal cancer: A systematic review.
  Lam K, Pan K, Linnekamp JF, Medema JP, Kandimalla R. Lam K, et al. Biochim Biophys Acta. 2016 Aug;1866(1):106-20. doi: 10.1016/j.bbcan.2016.07.001. Epub 2016 Jul 3. Biochim Biophys Acta. 2016. PMID: 27385266 Review.
• Diagnostic and prognostic epigenetic biomarkers in cancer.
  Costa-Pinheiro P, Montezuma D, Henrique R, Jerónimo C. Costa-Pinheiro P, et al. Epigenomics. 2015;7(6):1003-15. doi: 10.2217/epi.15.56. Epub 2015 Oct 7. Epigenomics. 2015. PMID: 26479312 Review.
• The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer.
  Gao D, Herman JG, Guo M. Gao D, et al. Oncotarget. 2016 Jun 14;7(24):37331-37346. doi: 10.18632/oncotarget.7949. Oncotarget. 2016. PMID: 26967246 Free PMC article. Review.
• Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.
  Grasse S, Lienhard M, Frese S, Kerick M, Steinbach A, Grimm C, Hussong M, Rolff J, Becker M, Dreher F, Schirmer U, Boerno S, Ramisch A, Leschber G, Timmermann B, Grohé C, Lüders H, Vingron M, Fichtner I, Klein S, Odenthal M, Büttner R, Lehrach H, Sültmann H, Herwig R, Schweiger MR. Grasse S, et al. Genome Med. 2018 Jul 20;10(1):55. doi: 10.1186/s13073-018-0562-1. Genome Med. 2018. PMID: 30029672 Free PMC article.

Cited by

• Identification of cuproptosis-related subtypes in lung adenocarcinoma and its potential significance.
  Pan S, Song C, Meng H, Li N, Li D, Hao B, Lu Z, Geng Q. Pan S, et al. Front Pharmacol. 2022 Oct 3;13:934722. doi: 10.3389/fphar.2022.934722. eCollection 2022. Front Pharmacol. 2022. PMID: 36263125 Free PMC article.
• Epigenetic Regulation of Hepatocellular Carcinoma Progression through the mTOR Signaling Pathway.
  Guo M, Li N, Zheng J, Wang W, Wu Y, Han X, Guo J, Chen W, Bai Z, Bai W, Wu J. Guo M, et al. Can J Gastroenterol Hepatol. 2021 May 25;2021:5596712. doi: 10.1155/2021/5596712. eCollection 2021. Can J Gastroenterol Hepatol. 2021. PMID: 34123955 Free PMC article. Review.
• Identifying anal and cervical tumorigenesis-associated methylation signaling with machine learning methods.
  Jian F, Huang F, Zhang YH, Huang T, Cai YD. Jian F, et al. Front Oncol. 2022 Sep 29;12:998032. doi: 10.3389/fonc.2022.998032. eCollection 2022. Front Oncol. 2022. PMID: 36249027 Free PMC article.
• Development of a Machine Learning Classifier for Brain Tumors Diagnosis Based on DNA Methylation Profile.
  Chen Y, Yan Y, Xu M, Chen W, Lin J, Zhao Y, Wu J, Wang X. Chen Y, et al. Front Bioinform. 2021 Nov 8;1:744345. doi: 10.3389/fbinf.2021.744345. eCollection 2021. Front Bioinform. 2021. PMID: 36303797 Free PMC article.
• Epigenomic dysregulation-mediated alterations of key biological pathways and tumor immune evasion are hallmarks of gingivo-buccal oral cancer.
  Das D, Ghosh S, Maitra A, Biswas NK, Panda CK, Roy B, Sarin R, Majumder PP. Das D, et al. Clin Epigenetics. 2019 Dec 3;11(1):178. doi: 10.1186/s13148-019-0782-2. Clin Epigenetics. 2019. PMID: 31796082 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations